Alembic Ltd, founded in 1907, is a veteran in India’s pharmaceutical sector, specializing in bulk drugs and formulations for human and animal healthcare. The company operates through three main segments: Bulk Drugs, Real Estate, and Power Generation, leveraging windmills and a co-gen power plant for captive energy needs. Alembic's pharmaceutical production aligns with international standards, holding ISO-9002 and ISO-14001 certifications and adhering to WHO-GMP guidelines.
With manufacturing units in Vadodara, Gujarat, and Solan, Himachal Pradesh, Alembic has a storied history of pioneering antibiotic production, including penicillin, erythromycin, and cephalosporins. Diversifying into lifestyle OTC products, Alembic launched a sucralose-based sugar substitute in 2005. The company has also ventured into real estate, completing projects like Samsara and VEDA. Strategic acquisitions and licensing agreements have bolstered its API capabilities. Recent structural changes, sanctioned in 2019, have optimized its real estate and engineering divisions, ensuring a focused growth trajectory.
